The FDA approved a the use of a drug combination that represents the first approved therapy in roughly 20 years for patients newly-diagnosed with diffuse large B-cell lymphoma, the non-Hodgkins lymphoma most prevalent in the U.S.
Published: Sunday, June 25th, 2023 @ 5:03 pm
By: Daily Wire
|